Capricor’s BLA for Deramiocel was granted Priority Review in March 2025 and was supported by data from the HOPE-2 trial, its open-label extension (OLE), and natural history comparisons from FDA-funded ...

Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are ...

Capricor TherapeuticsCAPR just hit that mark, with a jump from 69 to 86 Thursday. Please watch the video at Investors.com - ...

The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving ...